CT-Guided Percutaneous Radioactive 125I Brachytherapy for Locally Advanced Pancreatic Cancer.

IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Peng Du, Liangliang Meng, Zenan Chen, Xiao Zhang
{"title":"CT-Guided Percutaneous Radioactive <sup>125</sup>I Brachytherapy for Locally Advanced Pancreatic Cancer.","authors":"Peng Du, Liangliang Meng, Zenan Chen, Xiao Zhang","doi":"10.1177/10849785251380365","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To explore the efficacy and safety of <sup>125</sup>I source implantation via a coaxial puncture in treating locally advanced pancreatic cancer (LAPC). <b><i>Methods:</i></b> A retrospective analysis was used to investigate the efficacy and safety of 40 patients with LAPC treated with radioactive <sup>125</sup>I particles under CT guidance in the hospital. A treatment planning system was used to develop the preoperative plan, and the radioactive <sup>125</sup>I particles were implanted using a coaxial puncture technique in the same plane to simulate a sector distribution system. CT scans were performed at postoperative months 2, 4, and 6 for follow-up treatment outcome assessment. Overall survival (OS) time and progression-free survival (PFS) were calculated, and factors affecting prognosis were assessed. <b><i>Results:</i></b> All patients completed the operation successfully. The overall response rate of treatment at 2, 4, and 6 months was 37.5%, 47.5%, and 50.0%. The median OS and PFS were 11.0 months (95% confidence interval [CI]: 9.14-12.86) and 9.0 months (95% CI: 7.45-10.55), respectively. The 6- and 12-month PFS rates were 85.0% (95% CI: 69.6%-93.0%) and 35.0% (95% CI: 20.8%-49.5%), respectively. The 12-month OS rates were 47.5% (95% CI: 20.2%-49.8%). The intraoperative complications related to the operation were local abdominal hemorrhage in 2 cases, subcutaneous soft tissue hematoma in 2 cases, and wrong puncture of the pancreatic duct in 1 case. The main side-effects were fever in 10 cases and decreased appetite in 3 cases in the recent postoperative period. Eighteen grade 0 cases and 3 cases of grade I acute radiation enteritis occurred. No acute radiation damage above grade II and late radiation damage was observed. <b><i>Conclusions:</i></b> Coaxial puncture <sup>125</sup>I source implantation is a promising percutaneous minimally invasive technology that is safe and effective in treating LAPC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10849785251380365","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To explore the efficacy and safety of 125I source implantation via a coaxial puncture in treating locally advanced pancreatic cancer (LAPC). Methods: A retrospective analysis was used to investigate the efficacy and safety of 40 patients with LAPC treated with radioactive 125I particles under CT guidance in the hospital. A treatment planning system was used to develop the preoperative plan, and the radioactive 125I particles were implanted using a coaxial puncture technique in the same plane to simulate a sector distribution system. CT scans were performed at postoperative months 2, 4, and 6 for follow-up treatment outcome assessment. Overall survival (OS) time and progression-free survival (PFS) were calculated, and factors affecting prognosis were assessed. Results: All patients completed the operation successfully. The overall response rate of treatment at 2, 4, and 6 months was 37.5%, 47.5%, and 50.0%. The median OS and PFS were 11.0 months (95% confidence interval [CI]: 9.14-12.86) and 9.0 months (95% CI: 7.45-10.55), respectively. The 6- and 12-month PFS rates were 85.0% (95% CI: 69.6%-93.0%) and 35.0% (95% CI: 20.8%-49.5%), respectively. The 12-month OS rates were 47.5% (95% CI: 20.2%-49.8%). The intraoperative complications related to the operation were local abdominal hemorrhage in 2 cases, subcutaneous soft tissue hematoma in 2 cases, and wrong puncture of the pancreatic duct in 1 case. The main side-effects were fever in 10 cases and decreased appetite in 3 cases in the recent postoperative period. Eighteen grade 0 cases and 3 cases of grade I acute radiation enteritis occurred. No acute radiation damage above grade II and late radiation damage was observed. Conclusions: Coaxial puncture 125I source implantation is a promising percutaneous minimally invasive technology that is safe and effective in treating LAPC.

ct引导下经皮放射性125I近距离治疗局部晚期胰腺癌。
目的:探讨同轴穿刺125I源植入治疗局部晚期胰腺癌(LAPC)的有效性和安全性。方法:回顾性分析40例CT引导下放射性125I颗粒治疗LAPC的疗效和安全性。使用治疗计划系统制定术前计划,采用同轴穿刺技术在同一平面植入放射性125I粒子,模拟扇形分布系统。术后2、4、6个月进行CT扫描,随访治疗效果评估。计算总生存期(OS)和无进展生存期(PFS),并评估影响预后的因素。结果:所有患者均顺利完成手术。治疗2、4、6个月的总有效率分别为37.5%、47.5%、50.0%。中位OS和PFS分别为11.0个月(95%可信区间[CI]: 9.14-12.86)和9.0个月(95% CI: 7.45-10.55)。6个月和12个月的PFS分别为85.0% (95% CI: 69.6%-93.0%)和35.0% (95% CI: 20.8%-49.5%)。12个月OS率为47.5% (95% CI: 20.2%-49.8%)。术中出现腹部局部出血2例,皮下软组织血肿2例,胰管穿刺错误1例。术后近期主要副反应为发热10例,食欲下降3例。急性放射性肠炎0级18例,1级3例。未见II级以上急性辐射损伤和晚期辐射损伤。结论:同轴穿刺125I源植入术是一种安全、有效的经皮微创治疗LAPC技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.80
自引率
2.90%
发文量
87
审稿时长
3 months
期刊介绍: Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信